were included in the SHARP study and the Asia Pacific study; therefore, sorafenib is a widely approved agent for systemic therapy not only for advanced-stage HCC but also for unresectable HCC (including intermediate-stage HCC). In fact, sorafenib is often administered to patients with intermediate-stage HCC (BCLC-B) in clinical practice and to 16.4-19.6% of patients in clinical trials worldwide [3] [4] [5] .
Introduction
The SHARP study in 2007 [1] and the Asia Pacific study in 2008 [2] led to the worldwide approval of sorafenib as the standard therapy for unresectable hepatocellular carcinoma (HCC). However, clinical trials investigating sunitinib [3] , brivanib [4] , and linifanib [5] as first-line treatments, with sorafenib as a control arm, failed to meet their primary endpoint of improving overall survival (OS). In addition, global phase III studies investigating secondline therapy with brivanib [6] , everolimus [7] , and ramucirumab [8] , and a regional trial investigating S-1 (tegafur/gimeracil/oteracil) in Japan, were unsuccessful ( Table 1 ) . Thus, sorafenib was the only systemic therapeutic agent available for HCC, and for some time no options were available for patients with progressive disease or those intolerant to sorafenib. However, between June 2016 and January 2017, promising results of global phase III studies were reported. The results of a trial of regorafenib were reported at a conference [9] and in a journal [10] , and results with lenvatinib were reported in a press release [11] , indicating the arrival of a new era of liver cancer therapy. The results of the RESORCE study were published recently [10] . The success of the study is attributed to the following 3 points: (1) patients for whom sorafenib therapy was terminated because of adverse events were excluded from the trial, and second-line therapy with regorafenib was provided to HCC patients who had significant disease progression during sorafenib therapy; (2) vascular invasion and extrahepatic spread were considered as separate stratification factors to avoid imbalance in the 2 arms (test agent vs. placebo); and (3) patients showing tolerance to sorafenib (patients who tolerated 400 mg sorafenib daily for a minimum of 20 days within the last 28 days before radiological progression) were enrolled. This trial design prevented the risk of dropouts due to adverse events associated with regorafenib (since the toxicity of regorafenib is similar to that of sorafenib) and minimized the effect of post-trial treatment after disease progression [18] . According to the results of the RESORCE trial, the median OS (mOS) of patients treated with regorafenib was 10.6 months (7.8 for placebo; HR 0.63; p < 0.0001) ( Table 2 ). Subgroup analysis revealed that the HR of OS in patients with a Child-Pugh score of 5 was significantly better than that in patients with a Child-Pugh score of 6 (0.60 [0.40-0.79] vs. 0.80 [0.57-1.13]). This also supports the following approach to improving prognosis in the future: an early switch to sorafenib when patients become refractory to TACE and still have good liver function, such as with a Child-Pugh score of 5, with a subsequent switch to regorafenib as soon as possible after patients have shown progressive disease on sorafenib.
An exploratory analysis of the RESORCE trial showed a favorable OS of 26 months from the start of sorafenib therapy among patients who received sorafenib-regorafenib sequential therapy (19.2 months in the placebo group) [19] . These are extremely important data, because the 26-month prognosis is comparable with the conventional figure after TACE for patients with intermediate-stage HCC [20] . To date, 3 prospective phase III trials evaluating combination therapy with sorafenib and TACE have been performed ( Table 1 ) . The results of 2 of these trials have been published: the Japan-Korea TACE study ( n = 450) [21] and the brivanib-TACE (BRISK-TA) study, which evaluated adjuvant brivanib therapy in combination with TACE ( n = 502) [20] . Because the mOS was not reached in the placebo arm in the post-TACE study, the BRISK-TA study is currently the only prospective phase III study that investigated the OS with TACE and provided a valid mOS for the placebo arm. Since this was a randomized controlled trial (RCT) of TACE (with the largest number of patients included in any trial worldwide) and the placebo arm was free from selection bias, it provides standard outcomes for TACE worldwide. Additionally, most (82%) of the patients in the BRISK-TA study had ( Table 3 ) . Although comparing one arm from an RCT with an arm from exploratory analysis of a different RCT may not be appropriate, both were well-designed prospective randomized clinical trials that minimized the effect of selection bias. Considering that the patients in the sorafenib-regorafenib sequential therapy trial overwhelmingly had advanced-stage HCC, the OS in the study, which is comparable to that in BRISK-TA, is extremely impressive. There is no doubt that the group of subjects with advanced-stage HCC were superselected; nevertheless, the effect of sorafenib-regorafenib sequential therapy in patients with advanced-stage HCC is comparable to that of TACE in those for whom TACE is indicated.
Since the prognosis after sorafenib-regorafenib sequential therapy is promising, the appropriate time to start sorafenib therapy may need to be reconsidered. Conventionally, patients are switched from TACE to systemic therapy when they become refractory to TACE; however, a more proactive approach, such as the earlier introduction of systemic therapy to subgroups of patients who are likely to become refractory to TACE when their liver function is still preserved (Child-Pugh A), may be beneficial ( Fig. 1 ) .
Another unaddressed question is the proportion of patients who can be treated by sorafenib-regorafenib sequential therapy. In other words, even after the approval of regorafenib, further studies are needed to obtain real-world data on the percentage of patients undergoing sorafenib therapy who can complete the therapy and also complete regorafenib therapy after failure of sorafenib treatment and disease progression. However, the optimal time point to determine TACE refractoriness should not be missed, since the prognosis after sorafenib-regorafenib sequential therapy is good (26 months from the initiation of sorafenib therapy). Early identification of subgroups likely to become refractory to TACE is also important (Fig. 2) . The selection of patients who are likely to respond to systemic therapy is a valid and important line of inquiry regarding therapy with other agents, including lenvatinib (discussed below) and sorafenib. 
A New First-Line Therapy Option: Lenvatinib
Lenvatinib is an oral multi-tyrosine kinase receptor inhibitor that targets VEGF receptors 1-3, FGFR 1-4, PDGFRα, and the KIT and RET proto-oncogenes. It is approved worldwide for the treatment of radioactive iodine-refractory differentiated thyroid cancer. A phase II study evaluating lenvatinib for HCC treatment showed good outcomes, with an mOS of 18.7 months, a time to progression (TTP) of 7.4 months, an objective response rate (ORR) of 37%, and a disease control rate of 78% (according to the modified Response Evaluation Criteria in Solid Tumors [RECIST]) [22] . Considering that the ORR in the control arm of the BRISK-TA study was 42%, the ORR of 37% among those treated with lenvatinib may indicate that the levels of tumor necrosis induced by lenvatinib are similar to those induced by TACE ( Table 4 ) .
A worldwide press release by Eisai Co., Ltd. (January 25, 2017) revealed the results of the phase III REFLECT trial involving 954 patients with unresectable HCC [11] . Achievement of the primary endpoint (OS) in the lenvatinib trial was not inferior to that with sorafenib. The secondary endpoints (progression-free survival, TTP, and ORR) also showed that lenvatinib is statistically superior to sorafenib, with clinical significance. Details will be reported at relevant conferences and in journals. The approval of lenvatinib as a novel agent for unresectable HCC in Asia, Japan, Europe, and the USA is anticipated. The improvement of OS with lenvatinib, which is similar to that reported for sorafenib, will likely lead to the approval of lenvatinib as a first-line agent, in addition to sorafenib, for unresectable HCC.
Once lenvatinib will be approved and will become available for treating HCC patients, criteria for the differential use of lenvatinib and sorafenib in the clinical setting will need to be established. The benefits of sorafenib-regorafenib sequential therapy were demonstrated in a solid reliable prospective study [10, 19] . Second-line therapy with regorafenib resulted in significant improvement in patients who had suffered disease progression while on firstline sorafenib, with an mOS of 26 months from the start of sorafenib therapy, even in a group with predominantly advanced-stage HCC (BCLC-C) [19] . However, it is pertinent to note that the subject population was carefully selected.
On the other hand, lenvatinib showed clinically significant antitumor effects (progressionfree survival, TTP, and ORR) superior to sorafenib, as disclosed by a press release [11] and phase II trial results [22] . This therapeutic agent is expected to be as effective as TACE in terms of reducing tumor size and inducing tumor necrosis. In some cases, it is expected to permit conversion from systemic therapy to TACE or curative options such as resection or ablation [23] [24] [25] [26] . This is a potential advantage of lenvatinib.
For all intents and purposes, the arrival of regorafenib and lenvatinib provides the possibility of systemic therapy as an option for a subgroup of patients with intermediate-stage HCC who easily become or are refractory to TACE, in addition to those with advanced-stage HCC. Patients with intermediate-stage HCC who are likely to become refractory to TACE need to be identified to allow proactive intervention with systemic therapy ( Fig. 1 ) .
Conclusion
The results of phase III studies investigating 2 new therapeutic agents for HCC -namely, regorafenib and lenvatinib -were recently disclosed. The former was presented at a conference in June 2016, and results were published in a journal in January 2017; the latter was announced in a press release in January 2017. Sorafenib-regorafenib sequential therapy is of particular interest. The performance of lenvatinib will remain unclear until relevant congresses or publications; however, based on the contents of the press release, it is very likely to be indicated for the first-line treatment of unresectable HCCs. This suggests that additional therapeutic options will become available for patients with intermediate-stage (BCLC-B) as well as advanced-stage (BCLC-C) HCC.
